Mechanisms by which IGF-I may promote cancer

Cancer Biology and Therapy

Volumn 2, Issue 6, 2003, Pages 630-635

  Grimberg, Adda ^a  

^a NONE

Author keywords

Cancer; Insulin like growth factor (IGF); Insulin like growth factor binding proteins (IGFBPs); Insulinlike growth factor receptor (IGF 1R); Tyrosine kinase receptor

Indexed keywords

AKT1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL; BIOLOGICAL MODEL; BLOOD; CELL TRANSFORMATION; CHEMISTRY; HUMAN; METABOLISM; METASTASIS; NEOPLASM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RISK FACTORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4444370976     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.6.678     Document Type: Review

References (80)

1. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, et al. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986; 2503-12.
2. Ludwig T, Eggenschweiler J, Fisher P, D'ercole AJ, Davenport ML, Efstratiadis A. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev Biol 1996; 77:517-35.
3. Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 1993; 290:419-26. (Pubitemid 23094937)
4. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Eidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999; 5:1935-44. (Pubitemid 29334478)
5. Hwa V, Oh Y, Rosenfeld RG. The IGFBP superfamily. Endocr Rev 1999; 20:761-87.
6. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther 2002; 1:226-31.
7. Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B, Steenbergh PH, et al. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 1997; 272:31163-31171. (Pubitemid 27527567)
8. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Develop 1999; 13:2905-27.
9. Kaffer CR, Grinberg A, Pfeifer K. Regulatory mechanisms at the mouse Igf2/H19 locus. Molec Cell Biol 2001; 21:8189-96. (Pubitemid 33051807)
10. Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y, de La Chapelle A. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA 2001; 98:591-6. (Pubitemid 32105087)
11. DiGiovanni J, Bol DK, Wilker E, Beltran L, Carbajal S, Moats S, et al. Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. Cancer Res 2000; 60:1561-70. (Pubitemid 30183426)
12. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000; 97:3455-60. (Pubitemid 30183324)
13. Maiorano E, Ciampolillo A, Viale G, Maisonneuve P, Ambrosi A, Triggiani V, et al. Insulin-like growth factor 1 expression in thyroid tumors. Appl Immunohistochem Molec Morphol 2000; 8:110-9. (Pubitemid 30609971)
14. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1998; 83:1713-20. (Pubitemid 28501047)
15. Vella V, Sciacca L, Pandini G, Mineo R, Squatrito S, Vigneri R, et al. The IGF system in thyroid cancer: New concepts. Molec Pathol 2001; 54:121-4. (Pubitemid 32539600)
16. Grimberg A, Rajah R, Zhao H, Cohen P. The prostatic IGF System: New levels of complexity. In: Takano K, Hizuka N, Takahashi SI, eds. Molecular Mechanisms to Regulate the Activities of Insulin-Like Growth Factors. Amsterdam: Elsevier Science BV, 1998:205-13.
17. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75:1046-53.
18. Helle SI, Geisler S, Aas T, Paulsen T, Holly JM, Lonning PE. Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer. Brit J Cancer 2001; 85:74-7. (Pubitemid 32695719)
19. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277:38205-11. (Pubitemid 35154674)
20. Bustin SA, Dorudi S, Phillips SM, Feakins RM, Jenkins PJ. Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer. Tumour Biol 2002; 23:130-8. (Pubitemid 44858304)
21. Tang Y, Zhang D, Fallavollita L, Brodt P. Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res 2003; 63:1166-71. (Pubitemid 36348689)
22. Poulaki V, Mitsiades CS, McMullan C, Sykoutri D, Fanourakis G, Kotoula V, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab 2003; 88:5392-8. (Pubitemid 37452744)
23. Reinmuth N, Fan F, Liu W, Parikh AA, Stoeltzing O, Jung YD, et al. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 2002; l82:1377-89. (Pubitemid 35191541)
24. Clemmons DR, Maile LA. Minireview: Integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signaling. Endocrinol 2003; 144:1664-70. (Pubitemid 36543301)
25. Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol 2000; 148:399-404.
26. Guvakova MA, Adams JC, Boettiger D. Functional role of alpha-actinin, PI 3-kinase and MEK1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells. J Cell Sci 2002; 115:4149-65. (Pubitemid 35446810)
27. Wang F, Duan R, Chirgwin J, Safe SH. Transcriptional activation of cathepsin D gene expression by growth factors. J Molec Endocrinol 2000; 24:193-202. (Pubitemid 30187049)
28. Yoon A, Hurta RA. Insulin like growth factor-1 selectively regulates the expression of matrix metalloproteinase-2 in malignant H-ras transformed cells. Molec Cell Biochem 2001; 223:1-6. (Pubitemid 32952085)
29. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003; 22:974-82. (Pubitemid 36313141)
30. Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase. Cancer Res 2001; 61:1367-74. (Pubitemid 34292558)
31. Brodt P, Fallavollita L, Khatib AM, Samani AA, Zhang D. Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor beta subunit. J Biol Chem 2001; 276:33608-15.
32. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 1993; 90:11217-21. (Pubitemid 23354400)
33. Price JA, Kovach SJ, Johnson T, Koniaris LG, Cahill PA, Sitzmann JV, et al. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatol 2002; 36:1089-97. (Pubitemid 35253424)
34. Oksenberg D, Dieckmann BS, Greenberg PL. Functional interactions between colony-stimulating factors and the insulin family hormones for human myeloid leukemic cells. Cancer Res 1990; 50:6471-7. (Pubitemid 20348762)
35. Werner H, Shen-Orr Z, Rauscher 3rd FJ, Morris JF, Roberts Jr CT, LeRoith D. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Molec Cell Biol 1995; 15:3516-22.
36. Werner H, Karnieli E, Rauscher FJ, LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 1996; 93:8318-23. (Pubitemid 26269555)
37. Zhang L, Kashanchi F, Zhan Q, Zhan S, Brady JN, Fornace AJ, et al. Regulation of insulin-like growth factor II P3 promotor by p53: A potential mechanism for tumorigenesis. Cancer Res 1996; 56:1367-73. (Pubitemid 26080981)
38. Buckbinder L, Talbott R, Velasco Miguel S, Takenaka I, Faha B, Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377:646-9.
39. van Golen CM, Schwab TS, Ignatoski KM, Ethier SP, Feldman EL. PTEN/MMAC1 overexpression decreases insulin-like growth factor-I-mediated protection from apoptosis in neuroblastoma cells. Cell Growth Differen 2001; 12:371-8.
40. Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia BP, et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 2002; 21:5289-300. (Pubitemid 34948140)
41. Kim W, Kaelin Jr WG. The von Hippel-Lindau tumor suppressor protein: New insights into oxygen sensing and cancer. Curr Opin Genet Dev 2003; 13:55-60. (Pubitemid 36143928)
42. Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem 2000; 275:20700-6. (Pubitemid 30457658)
43. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncol 2002; 63:317-32. (Pubitemid 36151524)
44. Lai A, Sarcevic B, Prall OW, Sutherland RL. Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1). J Biol Chem 2001; 276:25823-33.
45. Hamelers IH, van Schaik RF, van Teeffelen HA, Sussenbach JS, Steenbergh PH. Synergistic proliferative action of insulin-like growth factor I and 17 beta-estradiol in MCF-7S breast tumor cells. Exptl Cell Res 2002; 273:107-17.
46. Stephen RL, Shaw LE, Larsen C, Corcoran D, Darbre PD. Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem 2001; 276:40080-6.
47. Campbell MJ, Woodside JV, Secker-Walker J, Titcomb A, Leathem AJ. IGF status is altered by tamoxifen in patients with breast cancer. Molec Pathol 2001; 54:307-10. (Pubitemid 32928256)
48. Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Torrisi R, Sandri MT, et al. Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Res Treat 2001; 69:21-7. (Pubitemid 33079026)
49. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54:5474-8.
50. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001; 61:6276-80.
51. Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 2000; 60:3058-64. (Pubitemid 30395835)
52. Damon SE, Plymate SR, Carroll JM, Sprenger CC, Dechsukhum C, Ware JL, et al. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinol 2001; 142:21-7. (Pubitemid 32183661)
53. Grimberg A, Cohen P. The role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183:1-9. (Pubitemid 30130219)
54. Oh Y, Müller HL, Pham H, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 1993; 268:26045-8. (Pubitemid 23361660)
55. Ricort JM, Lombet A, Lassarre C, Binoux M. Insulin-like growth factor binding protein-3 increases intracellular calcium concentrations in MCF-7 breast carcinoma cells. FEBS Let 2002; 527:293-7. (Pubitemid 35253882)
56. Ricort JM, Binoux M. Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity. Endocrinol 2001; 142:108-13. (Pubitemid 32183671)
57. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem 2000; 275:33607-13.
58. Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000; 275:39174-81. (Pubitemid 32058934)
59. Grimberg A. p53 and IGFBP-3: Apoptosis and cancer protection. Molec Genet Metab 2000; 70:85-98.
60. Grimberg A, Coleman CM, Burns TF, Himelstein BP, David R, Koch CJ, et al. p53-dependent and p53-independent induction of IGFBP-3 by DNA damage and hypoxia. The 84th Annual Meeting of The Endocrine Society Program and Abstracts 2002; 226.
61. Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P. IGFBP-3 mediates p53-induced apoptosis during serum starvation. Internatl J Oncol 2002; 21:327-35.
62. Grimberg A, Cohen P. GH and prostate cancer: Guilty by association? J Endocrinol Invest 1999; 22:64-73.
63. Pollak M. Insulin-like growth factor physiology and cancer risk. Europ J Cancer 2000; 36:1224-18.
64. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999; 96:7324-9. (Pubitemid 29299660)
65. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002; 62:1030-5. (Pubitemid 34160283)
66. Butler AA, Blakesley VA, Poulaki V, Tsokos M, Wood TL, LeRoith D, et al. Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression. Cancer Res 1998; 58:3021-7. (Pubitemid 28335082)
67. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci USA 1997; 94:5810-3. (Pubitemid 27241853)
68. Szepeshazi K, Schally AV, Groot K, Armatis P, Halmos G, Herbert F, et al. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Brit J Cancer 2000; 82:1724-31. (Pubitemid 30229585)
69. Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, et al. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Prostate 2002; 52:173-82. (Pubitemid 34791220)
70. Braczkowski R, Schally AV, Plonowski A, Varga JL, Groot K, Krupa M, et al. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: Effects on insulin-like growth factor II. Cancer 2002; 95:1735-45. (Pubitemid 35153465)
71. McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 2001; 94:487-92. (Pubitemid 32786030)
72. Pollak M, Blouin MJ, Zhang JC, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Brit J Cancer 2001; 85:428-30. (Pubitemid 32747713)
73. Lee CT, Park KH, Adachi Y, Seol JY, Yoo CG, Kim YW, et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther 2003; 10:57-63. (Pubitemid 36222077)
74. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003; 63:627-35. (Pubitemid 36158140)
75. Scotlandi K, Maini C, Manara MC, Benini S, Serra M, Cerisano V, et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 2002; 9:296-307. (Pubitemid 34205505)
76. Bohula EA, Salisbury AJ, Sohail M, Playford MP, Riedemann J, Southern EM, et al. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem 2003; 278:15991-7. (Pubitemid 36799718)
77. Ly A, Francois JC, Upegui-Gonzalez LC, Swiercz B, Bedel C, Duc HT, et al. Alterations in tumorigenicity of embryonal carcinoma cells by IGF-I triple-helix induced changes in immunogenicity and apoptosis. Life Sci 2000; 68:307-19.
78. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997; 57:4667-72. (Pubitemid 27468963)
79. Hursting SD, Perkins SN, Phang JM, Barrett JC. Diet and cancer prevention studies in p53-deficient mice. J Nutrit 2001; 131:3092S-4S.
80. Vainio H, Kaaks R, Bianchini F. Weight control and physical activity in cancer prevention: International evaluation of the evidence. Eur J Cancer Prevent 2002; 11 S2:S94-100.